Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | C1S | P09871 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357836 | 0.99 | MAPT (0.59) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6355125 | 0.83 | C1S (0.53) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6709132 | 0.83 | MAPT (0.52) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL25279844 | 0.82 | RAB9A (0.59) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL29654135 | 0.82 | MAPT (0.52) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| Bromide SCHEMBL8355363 | 0.79 | RAB9A (0.57) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12190708 | 0.78 | RAB9A (0.59) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3134094 | 0.78 | MAPT (0.72) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL31084656 | 0.78 | MAPT (0.72) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3610837 | 0.78 | ABL1 (0.56) | MAPTRAB9ASMN1; SMN2LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608650-A1 | PYRENE-LINKED PYRROLO(2,1-C)(1,4)BENZODIAZEPINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Council of Scientific and Industrial Research (IN) | 2005-12-28 | — | — | EP | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| WO-2004087711-A1 | PYRENE-LINKED PYRROLO (2,1-C) (1,4) BENZODIAZEPINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | COUNCIL OF SCENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-14 | — | — | WO | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | MAPT 3729/4885NPC1 3871/4885RAB9A 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.